Recro Pharma Inc. (REPH) announced Monday morning that its second of two Phase III clinical trials of intravenous meloxicam, for the treatment of acute postoperative pain, met its primary endpoint.
from RTT - Hot Stocks http://ift.tt/2fWWyTu
via IFTTT
No comments:
Post a Comment